ANTI-ANGIOGENIC COMPOSITION CONTAINING MACROLACTIN A AND A DERIVATIVE THEREOF AS ACTIVE INGREDIENTS
申请人:Daewoo Pharmaceutical Ind. Co., Ltd.
公开号:EP2594268A1
公开(公告)日:2013-05-22
The present invention relates to an anti-angiogenic composition containing macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A, and 7-O-succinyl macrolactin A as active ingredients. The macrolactin compounds according to the present invention strongly suppress angiogenesis in in vivo experiments and can be used as a pharmaceutical composition for preventing or treating diseases caused by angiogenesis.
本发明涉及一种抗血管生成组合物,其中含有大内酯化合物,如大内酯 A、7-O-丙二酰基大内酯 A 和 7-O-琥珀酰基大内酯 A 作为活性成分。根据本发明的大内酯化合物在体内实验中能强烈抑制血管生成,可用作预防或治疗由血管生成引起的疾病的药物组合物。
US8940788B2
申请人:——
公开号:US8940788B2
公开(公告)日:2015-01-27
[EN] COMPOSITION FOR PREVENTING OR TREATING SARS CORONAVIRUS 2 DISEASE<br/>[FR] COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE À CORONAVIRUS 2 RESPONSABLE DU SRAS<br/>[KO] 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
申请人:KYUNGSUNG UNIV INDUSTRY COOPERATION FOUNDATION
公开号:WO2021241873A1
公开(公告)日:2021-12-02
본 발명은 마크로락틴 유도체, 또는 이의 약학적으로 허용가능한 염을 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다.